# Illumina

Source: https://onco.cc/companies/illumina/  
OnCo record `illumina` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Illumina is the dominant DNA sequencing platform underneath nearly every genomic test in oncology.

## Summary

Illumina, based in San Diego and listed as ILMN, is the dominant DNA sequencing platform underneath nearly every genomic test in oncology. Its NovaSeq X instruments, the TruSight Oncology 500 panel, approved as an in vitro diagnostic in 2024 to 2025 and carried in OnCo as TruSight Oncology Comprehensive, and a constellation of measurable residual disease and spatial products make it the supplier behind many of the diagnostics companies on this site. OnCo links it to comprehensive genomic profiling and whole-genome sequencing, to new short-read sequencing platforms and clinical bioinformatics, to the CRUK Cambridge Institute, to Illumina Ventures and to the bottleneck that inherited risk is mostly unidentified. Whether new short-read competitors erode its position is the open question. TruSight Oncology Comprehensive has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: San Diego, CA
- Type: diagnostics
- Website: https://www.illumina.com
- Ticker: ILMN

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Illumina,_Inc.
- Official website: https://www.illumina.com

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Clinical NGS bioinformatics and variant interpretation](https://onco.cc/technologies/ngs-bioinformatics-software/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [New short-read sequencing platforms](https://onco.cc/technologies/next-gen-short-read-platforms/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- companies: [Illumina Ventures](https://onco.cc/companies/illumina-ventures/)
- bottlenecks: [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/)
- institutions: [Cancer Research UK Cambridge Centre / CRUK Cambridge Institute](https://onco.cc/institutions/cruk-cambridge-centre/)
- drugs: [TruSight Oncology Comprehensive](https://onco.cc/drugs/trusight-oncology-comprehensive/)

---
JSON: https://onco.cc/api/v1/entities/illumina.json